QCG
TEVA icon

Quadrant Capital Group’s Teva Pharmaceuticals TEVA Stock Holding History

Quadrant Capital Group’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$798K Sell
23,551
-789
-3% -$26.3K 0.02% 684
2026
Q1 		$733K Buy
24,340
+1,614
+7% +$51.9K 0.02% 711
2025
Q4 		$709K Buy
22,726
+836
+4% +$20.6K 0.02% 735
2025
Q3 		$442K Sell
21,890
-4,809
-18% -$84.5K 0.01% 942
2025
Q2 		$447K Buy
26,699
+6,946
+35% +$112K 0.02% 940
2025
Q1 		$304K Buy
19,753
+15,376
+351% +$275K 0.01% 1084
2024
Q4 		$96.5K Buy
4,377
+949
+28% +$17.3K 0.01% 1072
2024
Q3 		$61.8K Buy
3,428
+1,004
+41% +$17.6K ﹤0.01% 1342
2024
Q2 		$39.4K Buy
2,424
+383
+19% +$5.9K ﹤0.01% 1526
2024
Q1 		$28.8K Buy
2,041
+548
+37% +$6.91K ﹤0.01% 1683
2023
Q4 		$15.6K Sell
1,493
-866
-37% -$8.09K ﹤0.01% 1913
2023
Q3 		$24.1K Buy
2,359
+1,999
+555% +$18.6K ﹤0.01% 1625
2023
Q2 		$2.71K Sell
360
-1,331
-79% -$10.8K ﹤0.01% 2349
2023
Q1 		$15K Buy
1,691
+413
+32% +$4.08K ﹤0.01% 1836
2022
Q4 		$11.7K Buy
1,278
+364
+40% +$3.18K ﹤0.01% 1874
2022
Q3 		$7K Sell
914
-151
-14% -$1.33K ﹤0.01% 2037
2022
Q2 		$8K Buy
1,065
+812
+321% +$7.07K ﹤0.01% 1799
2022
Q1 		$2K Sell
253
-839
-77% -$7K ﹤0.01% 2198
2021
Q4 		$9K Buy
1,092
+716
+190% +$6.46K ﹤0.01% 1690
2021
Q3 		$4K Buy
376
+83
+28% +$777 ﹤0.01% 1969
2021
Q2 		$3K Sell
293
-23
-7% -$243 ﹤0.01% 2040
2021
Q1 		$4K Buy
316
+48
+18% +$550 ﹤0.01% 1892
2020
Q4 		$3K Buy
268
+179
+201% +$1.72K ﹤0.01% 1873
2020
Q3 		$1K Sell
89
-35
-28% -$370 ﹤0.01% 2062
2020
Q2 		$2K Sell
124
-15,154
-99% -$171K ﹤0.01% 1963
2020
Q1 		$137K Buy
15,278
+1,446
+10% +$14.8K 0.02% 476
2019
Q4 		$133K Buy
13,832
+13,797
+39,420% +$123K 0.02% 832
2019
Q3 		$0 Sell
35
-13,162
-100% -$101K ﹤0.01% 2385
2019
Q2 		$120K Buy
13,197
+6,333
+92% +$76.4K 0.02% 780
2019
Q1 		$104K Buy
6,864
+1,323
+24% +$23.3K 0.02% 790
2018
Q4 		$80K Buy
5,541
+4,476
+420% +$91.8K 0.02% 709
2018
Q3 		$19K Buy
1,065
+359
+51% +$8.34K 0.01% 1016
2018
Q2 		$15K Sell
706
-203
-22% -$4.14K 0.01% 1094
2018
Q1 		$11K Buy
909
+637
+234% +$12.4K ﹤0.01% 1229
2017
Q4 		$4K Sell
272
-122
-31% -$1.83K ﹤0.01% 1567
2017
Q3 		$4K Sell
394
-161
-29% -$3.62K ﹤0.01% 1563
2017
Q2 		$12K Sell
555
-233
-30% -$7.21K 0.01% 1056
2017
Q1 		$21K Buy
788
+342
+77% +$11.7K 0.01% 825
2016
Q4 		$13K Sell
446
-1,670
-79% -$66.7K 0.01% 949
2016
Q3 		$90K Buy
2,116
+1,276
+152% +$66.6K 0.06% 274
2016
Q2 		$37K Sell
840
-1,015
-55% -$54K 0.03% 501
2016
Q1 		$96K Sell
1,855
-781
-30% -$45.8K 0.06% 234
2015
Q4 		$167K Buy
2,636
+251
+11% +$15.5K 0.12% 155
2015
Q3 		$132K Buy
2,385
+1,000
+72% +$64.8K 0.09% 187
2015
Q2 		$80K Buy
+1,385
New +$85.4K 0.05% 308

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Quadrant Capital Group's TEVA Position: Q2 2026 in Review

Quadrant Capital Group reduced its Teva Pharmaceuticals (TEVA) stake by 3.2% in Q2 2026, selling an estimated $26.3K and leaving 23,551 shares worth $798K. The position accounts for 0.02% of the portfolio, ranked #684.

Quadrant Capital Group first reported a position in TEVA in Q2 2015 and has held it in 45 quarters since. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Quadrant Capital Group held 23,551 shares of Teva Pharmaceuticals worth $798K as of Q2 2026.
  • Quadrant Capital Group sold 789 Teva Pharmaceuticals shares in Q2 2026, an estimated $26.3K.
  • Teva Pharmaceuticals made up 0.02% of Quadrant Capital Group's portfolio in Q2 2026, its #684 holding.
  • Quadrant Capital Group first reported a position in Teva Pharmaceuticals in Q2 2015 and has held it in 45 quarters since.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.